BRISBANE, Calif., Nov. 4 /PRNewswire-FirstCall/ -- WHAT: VaxGen, Inc. Lance K. Gordon, Ph.D., VaxGen President and CEO, will present a company summary at the CIBC World Markets 16th Annual Healthcare Conference. The presentation will be available to the public through a webcast. WHERE/WHEN: Waldorf-Astoria Hotel, New York, NY 3:00p.m., EST, Wednesday, November 9, 2005 HOW: To listen and view the webcast presentation, go to Webcasts in the Investor Relations section of VaxGen’s web site at www.vaxgen.com/invest and click on CIBC 16th Annual Healthcare Conference. About VaxGen
VaxGen, Inc. is a biopharmaceutical company engaged in the development, manufacture and commercialization of biologic products for the prevention and treatment of human infectious diseases, including anthrax, smallpox and Meningitis B. The company has been awarded an $877.5 million U.S. government contract to provide 75 million doses of its recombinant anthrax vaccine for civilian biodefense. Based in Brisbane, Calif., VaxGen operates a wholly owned manufacturing facility in California and owns 22% of Celltrion, Inc., a South Korean operation established to provide contract manufacturing to the global pharmaceutical industry. For more information, please visit the company’s web site at: http://www.vaxgen.com .
(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO )
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk,photodesk@prnewswire.comVaxGen, Inc.
CONTACT: Pat Beaupre Becker of VaxGen, Inc., +1-650-624-1041
Web site: http://www.vaxgen.com/
